NCT05870839View on ClinicalTrials.gov

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

PHASE1CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions
SARS-CoVSARS-CoV-2
Interventions
BIOLOGICAL

VXCO-100

Sterile liquid for injection

Trial Locations (3)

14642

University of Rochester Medical Center - Vaccine Research Unit, Rochester

21201

University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore

30030

The Hope Clinic of Emory University, Decatur

All Listed Sponsors
lead

Vaccine Company, Inc.

INDUSTRY

NCT05870839 - Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States | Biotech Hunter | Biotech Hunter